AstraZeneca

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

CEO

Pascal Soriot

CEOPascal Soriot

Employees

94,300

Employees94,300

Headquarters

Cambridge, Cambridgeshire

HeadquartersCambridge, Cambridgeshire

Founded

1992

Founded1992

Employees

94,300

Employees94,300

AZN Key Statistics

Market cap

219.72B

Market cap219.72B

Price-Earnings ratio

28.05

Price-Earnings ratio28.05

Dividend yield

2.16%

Dividend yield2.16%

Average volume

4.27M

Average volume4.27M

High today

$71.97

High today$71.97

Low today

$70.27

Low today$70.27

Open price

$71.80

Open price$71.80

Volume

3.19M

Volume3.19M

52 Week high

$87.68

52 Week high$87.68

52 Week low

$61.24

52 Week low$61.24

AZN News

Seeking Alpha 11m

AstraZeneca’s rare disease drug falls short in late-stage trial

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell...

Benzinga 3h

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said tha...

TipRanks 4h

AstraZeneca’s Anselamimab Shows Promise in Subgroup of Amyloidosis Patients

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Analyst ratings

90%

of 30 ratings

Buy

90%

Hold

10%

Sell

More AZN News

TipRanks 4h

Positive Outlook on AstraZeneca’s Hypertension Treatment Pipeline Boosts Buy Rating

Leerink Partners analyst Andrew Berens maintained a Buy rating on AstraZeneca on July 14 and set a price target of $85.00. Elevate Your Investing Strategy: Ta...

TipRanks 18h

AstraZeneca’s DAISY Study: A New Hope for Systemic Sclerosis Treatment